- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05802446
Neurofeedback for Bipolar Disorder (NEUROFEED-BD)
Real-time fMRI Neurofeedback as Treatment for Inter-critical Mood Symptoms in Bipolar Disorder : a Randomized Controlled Multicentric Trial
Bipolar Disorder (BD) is a severe mood disorder affecting between 1% and 3% of the general population. It is characterized by the succession of depressive and manic episodes, with periods of stabilization during which patients may present "residual" depressive or anxious symptoms, which are characterized by sadness and emotional hyper-reactivity. Although subthreshold, these residual symptoms are very disabling for their daily lives and are associated with the risk of recurrence and poor global functioning. The effect of pharmacological and psychotherapeutic treatments is demonstrated in the management of acute episodes but remains insufficient on residual symptoms. Therefore, there are so far few therapeutic options to target the inter-episode residual symptoms in BD. One novel approach is the real-time functional magnetic resonance imaging (fMRI) neurofeedback (NFB), which has already been shown to be an efficient method for self-regulating brain function, behavior and treating depression.
Hypothesis/Objective :
This study aims at assessing the efficacy of 3-weeks neurofeedback training with real-time fMRI on the treatment of residual mood symptoms in patients with BD. The investigators will specifically target depressive symptoms by training the patients to regulate the emotional network hemodynamic response to emotional stimuli.
Method :
The investigators will include 64 stabilized patients with BD. The investigators will recruit them in three French expert centers for BD and will randomly assign them to the experimental group, receiving feedback from the emotional brain network hemodynamic activity, or to the control group, receiving the signal from control brain areas not involved in emotion processing. Both groups will be trained to regulate their brain activity while they are presented with negatively valenced emotional pictures, based on the neurofeedback shown immediately after the trial. They will continue their usual treatment (as prescribed) throughout the duration of the study. Clinical scales and cognitive tests will enable us to evaluate the symptomatic, emotional, and cognitive changes after NFB training. The investigators will also measure resting-state functional connectivity and brain morphology before and after NFB to assess brain plasticity and to explore the neural mechanisms associated with successful regulation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Josselin HOUENOU, Professor (MD, PhD)
- Phone Number: (+33)1 49 81 30 51
- Email: josselin.houenou@aphp.fr
Study Contact Backup
- Name: Pauline Favre, Associate researcher (PhD)
- Phone Number: (+33)1 69 08 24 81
- Email: pauline.favre@cea.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with bipolar disorder I or II (DSM-5 criteria);
- Aged between ≥ 18 and ≤ 65;
- Absence of major mood episode for at least 3 months before inclusion (MADRS scores < 12; YMRS score < 10);
- Presence of residual depressive symptoms, as assessed by the MADRS (score > 5);
- Stabilized dose of mood stabilizer medication for at least 3 months before inclusion.
- Written consent
- Affiliation to a social security system
- Effective contraception for women of childbearing age
Exclusion Criteria:
- Severe physical disorders that may be life-threatening;
- Major psychiatric (Axis 1) comorbidities except for anxiety disorders;
- Any current substance abuse except for tobacco or cannabis. Substance abuse will be defined by the DSM V criteria;
- Exclusion criteria applicable to MRI Panic disorder, claustrophobia, epilepsy Pace maker or neuronal stimulator, intraocular or intracerebral metallic foreign body, cochlear implant, cardiac valve or metallic surgical arterial material, non removable removable magnetizable metallic material
- Somatic disorder that may affect cognitive abilities and brain structures (e.g., HIV infection, MS, lupus, Parkinson's disease, epilepsy, dementia...);
- Ongoing non-pharmacological treatment: structured psychotherapeutic interventions (Cognitive Behavioral Therapy - CBT, Interpersonal and Social Rhythm Therapy - IPSRT) as well as brain stimulation techniques (Electroconvulsive Therapy - ECT, Transcranial Magnetic Stimulation - TMS, Deep Brain Stimulation - DBS);
- Subject included in clinical and / or therapeutic experimentation in progress.
- Patients under legal protection
- Prisoners
- Pregnancy
- Breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active feedback
Group receiving "real" neurofeedback (NFB) (activity of the emotional brain network)
|
Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant.
With this feedback on brain activity, subjects can learn to control the activity of selected brain areas.
Trial after trial, participants develop their individual strategies to voluntarily regulate the signal.
The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback.
By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
|
Sham Comparator: Sham feedback
Group receiving "sham" NFB (activity from brain regions not implicated in emotion processing) to control for a potential placebo effect.
|
Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant.
With this feedback on brain activity, subjects can learn to control the activity of selected brain areas.
Trial after trial, participants develop their individual strategies to voluntarily regulate the signal.
The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback.
By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Time Frame: Baseline, 3 weeks.
|
Evaluation of depressive symptoms.
Total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms.
|
Baseline, 3 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery and Asberg Depression Rating Scale (MADRS)
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of depressive symptoms.
Total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Young Mania Rating Scale (YMRS)
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of manic symptoms.
Total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Bipolar Depression Rating Scale (BDRS)
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of bipolar depression.
Total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
State-Trait Anxiety Inventory (STAI A-B)
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of trait and state anxiety.
Total score ranging from 20 to 80 for both subscales, with higher scores indicating a greater severity of symptoms.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Multidimensional Assessment of Thymic States - MAThyS
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of thymic state.
Total score ranging from 0 to 200, lower scores indicate general inhibition, and higher scores indicate general excitation.
A more descriptive approach can be done by analysing the sub-score.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Affective Intensity Measure - AIM
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of emotion reactivity.
Total score ranging from 20 to 120, with higher scores indicating higher strength or intensity of people's emotional experiences.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Affective Lability Scale - ALS
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of mood lability.
Total score ranging from 0 to 162, with higher scores indicating greater affective lability.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Cognitive Emotion Regulation Questionnaire - CERQ
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of emotion regulation abilities.
Subscales scores ranging from 4 to 20, with higher subscale scores indicating greater use of a specific cognitive strategy.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Quality of life scale - QOLS
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training. .
|
Quality of life assessment.
Score ranging from 1 to 5, 5 indicating better quality of life
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training. .
|
Five Facets Mindfulness Questionnaire - FFMQ
Time Frame: Baseline, 3 weeks and 4, 8 weeks after the end of the training.
|
Evaluation of trait mindfulness.
Total score ranging from 39 to 195, higher scores are indicative of someone who is more mindful in their everyday life
|
Baseline, 3 weeks and 4, 8 weeks after the end of the training.
|
Global functioning assessment - GAF scale
Time Frame: Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Evaluation of global functioning.
Total score ranging from 0 to 100, higher scores indicating better global functioning.
|
Baseline, 3 weeks, and 4, 8 weeks after the end of the training.
|
Questionnaire of Adherence to the technology
Time Frame: Baseline, 3 weeks.
|
Evaluation of the score of the acceptability of neurofeedback.
Total score ranging from 6 to 42, higher scores indicating better acceptability of the technology.
|
Baseline, 3 weeks.
|
Self-efficacy scale
Time Frame: Baseline, 3 weeks.
|
Evaluation of personal efficiency.
Total score ranging from 21 to 105, higher scores indicating stronger belief that one's actions are responsible for successful outcomes.
|
Baseline, 3 weeks.
|
The Ekman facial recognition test
Time Frame: Baseline, 3 weeks.
|
Emotion recognition evaluation.
Cognitive task
|
Baseline, 3 weeks.
|
The affective bias task
Time Frame: Baseline, 3 weeks.
|
Evaluation of emotional bias.
Cognitive task
|
Baseline, 3 weeks.
|
The Test battery for Attentional Performance (TAP)
Time Frame: Baseline, 3 weeks.
|
Evaluation of attention.
Cognitive task
|
Baseline, 3 weeks.
|
The choice reaction task
Time Frame: Baseline, 3 weeks.
|
Evaluation of mindwandering, meta-awareness and ruminations.
Cognitive task
|
Baseline, 3 weeks.
|
MRI T1-T2 weighted scan
Time Frame: Baseline, 3 weeks
|
Evaluation of grey and white matter (micro)structure.
MRI measurement
|
Baseline, 3 weeks
|
MRI diffusion weighted scan
Time Frame: Baseline, 3 weeks
|
Evaluation of grey and white matter (micro)structure.
MRI measurement
|
Baseline, 3 weeks
|
functional MRI resting-state scan
Time Frame: Baseline, 3 weeks
|
Evaluation of brain functional connectivity.
MRI measurement
|
Baseline, 3 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP180597
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
University Hospital, Strasbourg, FranceUnknownBipolar Disorder I | Bipolar Disorder II | Rapid Cycling Bipolar Disorder(DSM-IV-TR)France
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoNot yet recruitingBipolar Disorder | Bipolar Depression | Treatment- Resistant Bipolar Disorder | Type 2 Bipolar DisorderCanada
Clinical Trials on Real-time fMRI Neurofeedback
-
University of PittsburghCompleted
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedMajor Depressive DisorderUnited States
-
University of Electronic Science and Technology...Completed
-
Oklahoma State University Center for Health SciencesOklahoma State UniversityCompletedTesting Protocol With Healthy Individuals for FeasibilityUnited States
-
Yale UniversityCentral Institute of Mental Health, Mannheim; AE FoundationCompletedBorderline Personality DisorderUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingRumination | Depression in AdolescenceUnited States
-
Oklahoma State University Center for Health SciencesOklahoma State UniversityCompletedEmotional Dysfunction | Early Life StressUnited States
-
University of BernUniversity of ZurichActive, not recruiting
-
Kessler FoundationRecruitingStroke | Dyslexia, AcquiredUnited States